Ibogaine HCl (DMX-1002) for OUD

DemeRx are planning to conduct a Phase II proof of concept study investigating the effects of their DMX-1002 formulation for the treatment of Opioid Use Disorder.

DMX-1002 is an ibogaine formulation.

DemeRx has received approval from the UK Medicines and Healthcare products Regulatory Agency to commence enrolment for a Phase I/IIa clinical trial.

Topic Addiction Opioid Use Disorder
Compound Ibogaine
Country United Kingdom
Visit trial
Status Planned
Results Published No
Chance of happening 89%
Design Open
Type Interventional
Generation Second
Sex All
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

DemeRx
DemeRx is a subsidiary of atai that aims to develop ibogaine for Opioid Use Disorder.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.